An update on NIH RECOVER-TLC treatment trials, including baricitinib, low-dose naltrexone, semaglutide, and stellate ganglion block.
About 80% of U.S. long COVID specialty clinics have closed as of 2025, driven by funding cuts, provider burnout, and the lack of approved treatments.
A comprehensive review describing Long COVID as a multisystem disorder affecting nearly every organ system, estimated to affect 400 million people globally.
Ed Yong explains that long COVID brain fog is fundamentally a disorder of executive function, not simple forgetfulness — and why it's so often dismissed.
An influential economic analysis estimates 2 to 4 million working-age Americans are out of work due to long COVID, costing $170-230 billion a year.
A year after infection, two patient-advocate co-authors argue long COVID is a mass-disabling event still largely ignored by policymakers.